Nam Ha Pharmaceutical Joint Stock Company
UUPCOM:NHD54,000.00
VND
-1,000.00
(-1.82%)
ISIN
VN000000NHD6
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ninh Binh Vietnam
- Website
- namhapharma.com
- Similar Companies
- Business
- Nam Ha Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical manufacturer and distributor specializing in the research, development, production, and commercialization of modern medicines, traditional herbal remedies, and dietary supplements. Founded in 1960 and headquartered in Nam Dinh, Vietnam, the company operates across several core business segments, offering a systematic portfolio that includes traditional phytotherapeutic medicines, highlighted by its flagship Bo Phe Nam Ha cough relief product line available in syrups, lozenges, and oral sprays; over-the-counter and prescription pharmaceutical formulations, including antibiotics, analgesics, antipyretics, cardiovascular drugs, and gastrointestinal treatments; health supplements, vitamins, and herbal tonics designed for hepatoprotection, digestive support, and immunity enhancement; topical solutions, nasal sprays, and antiseptic preparations; and comprehensive contract manufacturing, packaging, and logistics services. Nam Ha Pharmaceutical distributes its products domestically through an extensive network of hospitals, clinics, and retail pharmacies across Vietnam, while also exporting select herbal and pharmaceutical products to regional international markets. In recent operational developments, the company has expanded its manufacturing capabilities with upgraded GMP-WHO certified facilities, established and widened GACP-WHO certified medicinal herb cultivation zones to ensure supply-chain traceability, introduced new product variants including sugar-free formulations of its core remedies to address evolving healthcare demographics, and accelerated the digital transformation of its nationwide distribution and supply chain operations.